Oncology News | pharmaphorum

News

Let’s Talk Prostate Cancer calls for action by MEPs

An organisation representing the interests of patients with prostate cancer has published a manifesto ahead of the EU elections next year, calling for more screening for t

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

News

Owkin and MSD join forces on AI-powered digital pathology

Pharma group MSD has joined forces with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for

News

FDA says no to Checkpoint’s skin cancer drug cosibelimab

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatm

News

Illumina admits defeat in Grail quest, opting to divest

Illumina has said it will divest cancer detection company Grail, marking the end of a long-running antitrust dispute that has claimed the jobs of its former CEO and chair.

Let’s Talk Prostate Cancer calls for action by MEPs

Sanofi drops lung cancer ADC tusamitamab ravtansine

GSK taps Hansoh for another cancer ADC candidate

Owkin and MSD join forces on AI-powered digital pathology

FDA says no to Checkpoint’s skin cancer drug cosibelimab

Illumina admits defeat in Grail quest, opting to divest

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks